•
Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal, led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team, values the business at approximately JPY 510 billion…
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s Laboratories Ltd. (BOM: 500124) for its HLX15, a biosimilar version of Johnson & Johnson’s Darzalex (daratumumab). Under the agreement, Dr. Reddy’s will obtain exclusive commercialization rights to the anti-CD38 monoclonal antibody (mAb), including both intravenous…
•
China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market…
•
Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD 12.3 billion during Q4 2024, excluding foreign exchange impact. For the full year, revenues rose 7% YOY to USD 48.3 billion, according to the company’s financial report released this week. The US market expanded 9%…
•
China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for its adsorbed tetanus vaccine for review. The vaccine is indicated for the prevention of non-neonatal tetanus. This acceptance marks a significant milestone in the development and…
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study for its interleukin-17 (IL-17) monoclonal antibody (mAb) HB0017 in hidradenitis suppurativa (HS) after receiving approval from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of novel treatments for…
•
China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) AA001. The drug is intended for the treatment of mild cognitive impairment caused by Alzheimer’s disease (AD) and mild to moderate AD. This…
•
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of the pivotal Phase III waveLINE-010 study. This study is designed to assess zilovertamab vedotin, an investigational antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with rituximab plus cyclophosphamide, doxorubicin, and…
•
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase III study assessing its Epidaza (chidamide) combined with CHOP in naive, peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH). This approval marks a significant step…
•
Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that they have received approval from the National Medical Products Administration (NMPA) to conduct a Phase III clinical study for JSKN003 versus trastuzumab emtansine in HER2-positive advanced breast cancer. This approval marks a significant milestone in…
•
Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from the National Medical Products Administration (NMPA) for its GC310, an adeno-associated virus (AAV) gene therapy for hepatolenticular degeneration, also known as Wilson’s disease. This approval marks a significant step forward in the development of a…
•
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its HX044. This follows the initiation of a Phase I study for the CTLA-4 bispecific antibody (BsAb) in Australia. The approval marks a significant step in the global…
•
Beijing-based cell therapy developer Likang Life Sciences announced that it has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials for its LK101, an mRNA neoantigen vaccine. This marks a significant milestone in the development of personalized cancer treatments. Innovative Vaccine TechnologyLK101 is an innovative…
•
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, has received approval from the State-owned Assets Supervision and Administration Commission of the State Council (SASAC) to acquire an aggregate of 418,306,002 shares of compatriot firm Tasly Pharma Co., Ltd (SHA: 600535). According to the deal struck in August of last…
•
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion this week regarding the approval of a subcutaneous (SC) formulation of Johnson & Johnson’s (J&J, NYSE: JNJ) Rybrevant (amivantamab). The recommendation covers the drug’s use in combination with Lazcluze (lazertinib) for…
•
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) assessing its PD-1/VEGF bispecific antibody (BsAb) ivonescimab. The trial compares ivonescimab combined with platinum-based chemotherapy to PD-1 inhibitor tislelizumab in combination with platinum-based chemotherapy in first-line squamous non-small cell lung…
•
Bayer AG (FRA: BAYN) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with…
•
Boston Scientific Corporation (NYSE: BSX) released its Q4 and full-year 2024 financial report, showing robust growth across its business segments and geographies. Over the 12 months, the firm’s global net revenues reached USD 16.75 billion, up 17.6% year-on-year (YOY) in constant currency terms. During Q4’24, the US major recorded USD…
•
Suzhou-based Vigonvita Life Sciences Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking a listing on the bourse. This move marks a significant step for the company as it looks to expand its market presence and raise capital for future growth. Company…
•
The National Healthcare Security Administration (NHSA) has released a set of regulations aimed at improving the management of Diagnosis Related Groups (DRG) and Diagnosis-Intervention Packet (DIP) payment methods under the multi-level medical security system of “1+3+N”. The document emphasizes the need for better coordination between payment methods and reforms in…